[1]. Ahmad H, et al. Pitavastatin: a new HMG-CoA reductase inhibitor for the treatment of hypercholesterolemia. Cardiol Rev, 2010, 18(5):264-267.
[2]. Olsson AG, et al. Rosuvastatin: a highly effective new HMG-CoA reductase inhibitor.Cardiovasc Drug Rev. 2002, 20(4):303-28.
[3]. Ohnaka K, et al. Pitavastatin enhanced BMP-2 and osteocalcin expression by inhibition of Rho-associated kinase in human osteoblasts. Biochem Biophys Res Commun, 2001, 287(2), 337-342.
[4]. Martin G, et al. Statin-induced inhibition of the Rho-signaling pathway activates PPARalpha and induces HDL apoA-I. J Clin Invest, 2001, 107(11), 1423-1432.
[5]. You HY, et al. Pitavastatin suppressed liver cancer cells in vitro and in vivo. Onco Targets Ther. 2016, 9:5383-8. [6] Hu W, et al. Pitavastatin-attenuated cardiac dysfunction in mice with dilated cardiomyopathy via regulation of myocardial calcium handling proteins. Acta Pharm. 2014, 64(1):105-15.
[6]. Hu W, et al. Pitavastatin-attenuated cardiac dysfunction in mice with dilated cardiomyopathy via regulation of myocardial calcium handling proteins. Acta Pharm. 2014, 64(1):105-15.